In the last 12 months, insiders at ENANTA PHARMACEUTICALS INC ($ENTA) filed 118 transactions with the SEC: 1 open-market purchases totaling $256,050 and 19 sales totaling $590,497. Net insider sentiment: net selling.
ENANTA PHARMACEUTICALS INC operates in the Pharmaceutical preparations industry (Life sciences sector).
Most Active Insiders
- Luly Jay R. (President and CEO) — 14 transactions totaling $573,735
- Rottinghaus Scott T. (Chief Medical Officer) — 19 transactions totaling $390,837
- Kieffer Tara Lynn (Chief Product Strategy Officer) — 14 transactions totaling $232,147
- Or Yat Sun (Chief Scientific Officer) — 13 transactions totaling $165,452
- Luu Brendan (Chief Business Officer) — 13 transactions totaling $128,825
View all SEC Filings for ENANTA PHARMACEUTICALS INC (ENTA).
Set Up your own filters →Recent Insider Transactions
| Transaction Date | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|
| March 11, 2026 | Vance Terry | Director | A | Stock Option (right to buy) | 20000 | $0.00 | 20,000.0000 | 29,019,344 | 9999.99% | 0.07% |
| March 11, 2026 | CARTER BRUCE L A | Director | A | Stock Option (right to buy) | 20000 | $0.00 | 20,000.0000 | 29,019,344 | 9999.99% | 0.07% |
| March 11, 2026 | FOLETTA MARK G | Director | A | Stock Option (right to buy) | 20000 | $0.00 | 20,000.0000 | 29,019,344 | 9999.99% | 0.07% |
| March 11, 2026 | Hata Yujiro S | Director | A | Stock Option (right to buy) | 20000 | $0.00 | 20,000.0000 | 29,019,344 | 9999.99% | 0.07% |
| March 11, 2026 | Peterson Kristine | Director | A | Stock Option (right to buy) | 20000 | $0.00 | 20,000.0000 | 29,019,344 | 9999.99% | 0.07% |
| March 11, 2026 | Russell Lesley | Director | A | Stock Option (right to buy) | 20000 | $0.00 | 20,000.0000 | 29,019,344 | 9999.99% | 0.07% |
| Feb. 12, 2026 | Luu Brendan | Chief Business Officer | F | Common Stock | 3257 | $14.25 | 41,634.0000 | 29,019,344 | 7.26% | 0.01% |
| Feb. 12, 2026 | Kieffer Tara Lynn | Chief Product Strategy Officer | A | Common Stock | 1575 | $0.00 | 32,195.0000 | 29,019,344 | 5.14% | 0.01% |
| Feb. 12, 2026 | Kieffer Tara Lynn | Chief Product Strategy Officer | A | Common Stock | 4987 | $0.00 | 37,182.0000 | 29,019,344 | 15.49% | 0.02% |
| Feb. 12, 2026 | Kieffer Tara Lynn | Chief Product Strategy Officer | F | Common Stock | 3257 | $14.25 | 33,925.0000 | 29,019,344 | 8.76% | 0.01% |
| Feb. 12, 2026 | Rottinghaus Scott T. | Chief Medical Officer | A | Common Stock | 1650 | $0.00 | 23,442.0000 | 29,019,344 | 7.57% | 0.01% |
| Feb. 12, 2026 | Rottinghaus Scott T. | Chief Medical Officer | A | Common Stock | 5225 | $0.00 | 28,667.0000 | 29,019,344 | 22.29% | 0.02% |
| Feb. 12, 2026 | Rottinghaus Scott T. | Chief Medical Officer | F | Common Stock | 3413 | $14.25 | 25,254.0000 | 29,019,344 | 11.91% | 0.01% |
| Feb. 12, 2026 | Or Yat Sun | Chief Scientific Officer | A | Common Stock | 1650 | $0.00 | 373,042.0000 | 29,019,344 | 0.44% | 0.01% |
| Feb. 12, 2026 | Or Yat Sun | Chief Scientific Officer | A | Common Stock | 5225 | $0.00 | 378,267.0000 | 29,019,344 | 1.40% | 0.02% |
| Feb. 12, 2026 | Or Yat Sun | Chief Scientific Officer | F | Common Stock | 3413 | $14.25 | 374,854.0000 | 29,019,344 | 0.90% | 0.01% |
| Feb. 12, 2026 | Luly Jay R. | President and CEO | A | Common Stock | 4800 | $0.00 | 862,826.0000 | 29,019,344 | 0.56% | 0.02% |
| Feb. 12, 2026 | Luly Jay R. | President and CEO | A | Common Stock | 15200 | $0.00 | 878,026.0000 | 29,019,344 | 1.76% | 0.05% |
| Feb. 12, 2026 | Luly Jay R. | President and CEO | F | Common Stock | 6155 | $14.25 | 871,871.0000 | 29,019,344 | 0.70% | 0.02% |
| Feb. 12, 2026 | Kowalsky Matthew Paul | Chief Legal Officer | A | Common Stock | 1318 | $0.00 | 1,318.0000 | 29,019,344 | 9999.99% | 0.00% |
| Feb. 12, 2026 | Kowalsky Matthew Paul | Chief Legal Officer | A | Common Stock | 4175 | $0.00 | 5,493.0000 | 29,019,344 | 316.77% | 0.01% |
| Feb. 12, 2026 | Kowalsky Matthew Paul | Chief Legal Officer | F | Common Stock | 1902 | $14.25 | 3,591.0000 | 29,019,344 | 34.63% | 0.01% |
| Feb. 12, 2026 | Luu Brendan | Chief Business Officer | A | Common Stock | 1575 | $0.00 | 39,904.0000 | 29,019,344 | 4.11% | 0.01% |
| Feb. 12, 2026 | Luu Brendan | Chief Business Officer | A | Common Stock | 4987 | $0.00 | 44,891.0000 | 29,019,344 | 12.50% | 0.02% |
| Dec. 5, 2025 | Trout Harry R. III | See Remarks | S | Common Stock | 542 | $14.23 | 16,348.0000 | 28,862,601 | 3.21% | 0.00% |
| Dec. 5, 2025 | Luly Jay R. | President and CEO | S | Common Stock | 4743 | $14.23 | 858,026.0000 | 28,862,601 | 0.55% | 0.02% |
| Dec. 5, 2025 | Or Yat Sun | Chief Scientific Officer | S | Common Stock | 2390 | $14.23 | 371,392.0000 | 28,862,601 | 0.64% | 0.01% |
| Dec. 5, 2025 | Kieffer Tara Lynn | Chief Product Strategy Officer | S | Common Stock | 2106 | $14.23 | 30,620.0000 | 28,862,601 | 6.44% | 0.01% |
| Dec. 5, 2025 | Luu Brendan | Chief Business Officer | S | Common Stock | 1394 | $14.23 | 38,329.0000 | 28,862,601 | 3.51% | 0.00% |
| Dec. 5, 2025 | Rottinghaus Scott T. | Chief Medical Officer | S | Common Stock | 798 | $14.23 | 21,792.0000 | 28,862,601 | 3.53% | 0.00% |
| Dec. 5, 2025 | Capps Kathleen S. | See Remarks | S | Common Stock | 323 | $14.23 | 8,377.0000 | 28,862,601 | 3.71% | 0.00% |
| Dec. 1, 2025 | Trout Harry R. III | See Remarks | F | Common Stock | 105 | $14.12 | 17,270.0000 | 28,862,601 | 0.60% | 0.00% |
| Dec. 1, 2025 | Capps Kathleen S. | See Remarks | F | Common Stock | 85 | $14.12 | 8,907.0000 | 28,862,601 | 0.95% | 0.00% |
| Dec. 1, 2025 | Luly Jay R. | President and CEO | F | Common Stock | 1885 | $14.12 | 862,769.0000 | 28,862,601 | 0.22% | 0.01% |
| Dec. 1, 2025 | Or Yat Sun | Chief Scientific Officer | F | Common Stock | 753 | $14.12 | 373,782.0000 | 28,862,601 | 0.20% | 0.00% |
| Dec. 1, 2025 | Kieffer Tara Lynn | Chief Product Strategy Officer | F | Common Stock | 753 | $14.12 | 32,726.0000 | 28,862,601 | 2.25% | 0.00% |
| Dec. 1, 2025 | Luu Brendan | Chief Business Officer | F | Common Stock | 498 | $14.12 | 39,723.0000 | 28,862,601 | 1.24% | 0.00% |
| Dec. 2, 2025 | Trout Harry R. III | See Remarks | S | Common Stock | 380 | $13.96 | 16,890.0000 | 28,862,601 | 2.20% | 0.00% |
| Dec. 2, 2025 | Capps Kathleen S. | See Remarks | S | Common Stock | 207 | $13.96 | 8,700.0000 | 28,862,601 | 2.32% | 0.00% |
| Nov. 25, 2025 | Capps Kathleen S. | See Remarks | A | Common Stock | 3163 | $0.00 | 8,992.0000 | 28,862,601 | 54.26% | 0.01% |
| Nov. 25, 2025 | Luly Jay R. | President and CEO | A | Stock Option (right to buy) | 310000 | $0.00 | 310,000.0000 | 28,862,601 | 9999.99% | 1.07% |
| Nov. 25, 2025 | Or Yat Sun | Chief Scientific Officer | A | Stock Option (right to buy) | 110000 | $0.00 | 110,000.0000 | 28,862,601 | 9999.99% | 0.38% |
| Nov. 25, 2025 | Capps Kathleen S. | See Remarks | A | Stock Option (right to buy) | 6325 | $0.00 | 6,325.0000 | 28,862,601 | 9999.99% | 0.02% |
| Nov. 25, 2025 | Trout Harry R. III | See Remarks | A | Common Stock | 6463 | $0.00 | 17,375.0000 | 28,862,601 | 59.23% | 0.02% |
| Nov. 25, 2025 | Trout Harry R. III | See Remarks | A | Stock Option (right to buy) | 12925 | $0.00 | 12,925.0000 | 28,862,601 | 9999.99% | 0.04% |
| Nov. 25, 2025 | Luu Brendan | Chief Business Officer | A | Stock Option (right to buy) | 90000 | $0.00 | 90,000.0000 | 28,862,601 | 9999.99% | 0.31% |
| Nov. 25, 2025 | Kieffer Tara Lynn | Chief Product Strategy Officer | A | Stock Option (right to buy) | 100000 | $0.00 | 100,000.0000 | 28,862,601 | 9999.99% | 0.35% |
| Nov. 25, 2025 | Kowalsky Matthew Paul | Chief Legal Officer | A | Stock Option (right to buy) | 90000 | $0.00 | 90,000.0000 | 28,862,601 | 9999.99% | 0.31% |
| Nov. 25, 2025 | Rottinghaus Scott T. | Chief Medical Officer | A | Stock Option (right to buy) | 110000 | $0.00 | 110,000.0000 | 28,862,601 | 9999.99% | 0.38% |
| Aug. 8, 2025 | Rottinghaus Scott T. | Chief Medical Officer | F | Common Stock | 2217 | $6.99 | 22,590.0000 | 21,377,923 | 8.94% | 0.01% |
| March 13, 2025 | Vance Terry | Director | A | Stock Option (right to buy) | 15700 | $0.00 | 15,700.0000 | 0 | 9999.99% | 0.00% |
| March 13, 2025 | FOLETTA MARK G | Director | A | Stock Option (right to buy) | 15700 | $0.00 | 15,700.0000 | 0 | 9999.99% | 0.00% |
| March 13, 2025 | Hata Yujiro S | Director | A | Stock Option (right to buy) | 15700 | $0.00 | 15,700.0000 | 0 | 9999.99% | 0.00% |
| March 13, 2025 | Peterson Kristine | Director | A | Stock Option (right to buy) | 15700 | $0.00 | 15,700.0000 | 0 | 9999.99% | 0.00% |
| March 13, 2025 | Russell Lesley | Director | A | Stock Option (right to buy) | 15700 | $0.00 | 15,700.0000 | 0 | 9999.99% | 0.00% |
| March 13, 2025 | CARTER BRUCE L A | Director | A | Stock Option (right to buy) | 15700 | $0.00 | 15,700.0000 | 0 | 9999.99% | 0.00% |
| Feb. 12, 2025 | Or Yat Sun | Chief Scientific Officer | F | Common Stock | 4324 | $5.59 | 374,535.0000 | 0 | 1.14% | 0.00% |
| Feb. 12, 2025 | Luu Brendan | Chief Business Officer | A | Common Stock | 7500 | $0.00 | 43,547.0000 | 0 | 20.81% | 0.00% |
| Feb. 12, 2025 | Luu Brendan | Chief Business Officer | F | Common Stock | 3326 | $5.59 | 40,221.0000 | 0 | 7.64% | 0.00% |
| Feb. 12, 2025 | Kieffer Tara Lynn | Chief Product Strategy Officer | A | Common Stock | 7500 | $0.00 | 36,805.0000 | 0 | 25.59% | 0.00% |
| Feb. 12, 2025 | Kieffer Tara Lynn | Chief Product Strategy Officer | F | Common Stock | 3326 | $5.59 | 33,479.0000 | 0 | 9.04% | 0.00% |
| Feb. 12, 2025 | Rottinghaus Scott T. | Chief Medical Officer | A | Common Stock | 9750 | $0.00 | 27,668.0000 | 0 | 54.41% | 0.00% |
| Feb. 12, 2025 | Rottinghaus Scott T. | Chief Medical Officer | F | Common Stock | 2861 | $5.59 | 24,807.0000 | 0 | 10.34% | 0.00% |
| Feb. 12, 2025 | Or Yat Sun | Chief Scientific Officer | A | Common Stock | 9750 | $0.00 | 378,859.0000 | 0 | 2.64% | 0.00% |
| Feb. 12, 2025 | MELLETT PAUL J | Chief Fin. & Admin Officer | A | Common Stock | 7500 | $0.00 | 99,210.0000 | 0 | 8.18% | 0.00% |
| Feb. 12, 2025 | MELLETT PAUL J | Chief Fin. & Admin Officer | F | Common Stock | 3326 | $5.59 | 95,884.0000 | 0 | 3.35% | 0.00% |
| Feb. 12, 2025 | Luly Jay R. | President and CEO | A | Common Stock | 25500 | $0.00 | 872,138.0000 | 0 | 3.01% | 0.00% |
| Feb. 12, 2025 | Luly Jay R. | President and CEO | F | Common Stock | 7484 | $5.59 | 864,654.0000 | 0 | 0.86% | 0.00% |
| Feb. 12, 2025 | Luly Jay R. | President and CEO | P | Common Stock | 45000 | $5.69 | 846,638.0000 | 0 | 5.61% | 0.00% |
| Dec. 6, 2024 | Kieffer Tara Lynn | Chief Product Strategy Officer | S | Common Stock | 2283 | $8.06 | 29,305.0000 | 0 | 7.23% | 0.00% |
| Dec. 6, 2024 | Luly Jay R. | President and CEO | S | Common Stock | 5142 | $8.06 | 801,638.0000 | 0 | 0.64% | 0.00% |
| Dec. 6, 2024 | Rottinghaus Scott T. | Chief Medical Officer | S | Common Stock | 866 | $8.06 | 17,918.0000 | 0 | 4.61% | 0.00% |
| Dec. 6, 2024 | Or Yat Sun | Chief Scientific Officer | S | Common Stock | 2591 | $8.06 | 369,109.0000 | 0 | 0.70% | 0.00% |
| Dec. 6, 2024 | MELLETT PAUL J | Chief Fin. & Admin Officer | S | Common Stock | 2591 | $8.06 | 91,710.0000 | 0 | 2.75% | 0.00% |
| Dec. 6, 2024 | Luu Brendan | Chief Business Officer | S | Common Stock | 2283 | $8.06 | 36,047.0000 | 0 | 5.96% | 0.00% |
| Dec. 1, 2024 | MELLETT PAUL J | Chief Fin. & Admin Officer | F | Common Stock | 1595 | $8.60 | 94,301.0000 | 0 | 1.66% | 0.00% |
| Dec. 1, 2024 | Luu Brendan | Chief Business Officer | F | Common Stock | 753 | $8.60 | 38,330.0000 | 0 | 1.93% | 0.00% |
| Dec. 1, 2024 | Kieffer Tara Lynn | Chief Product Strategy Officer | F | Common Stock | 753 | $8.60 | 31,588.0000 | 0 | 2.33% | 0.00% |
| Dec. 1, 2024 | Or Yat Sun | Chief Scientific Officer | F | Common Stock | 1595 | $8.60 | 371,700.0000 | 0 | 0.43% | 0.00% |
| Dec. 1, 2024 | Luly Jay R. | President and CEO | F | Common Stock | 3829 | $8.60 | 806,780.0000 | 0 | 0.47% | 0.00% |
| Nov. 27, 2024 | MELLETT PAUL J | Chief Fin. & Admin Officer | A | Stock Option (right to buy) | 81000 | $0.00 | 81,000.0000 | 0 | 9999.99% | 0.00% |
| Nov. 27, 2024 | Kowalsky Matthew Paul | Chief Legal Officer | A | Stock Option (right to buy) | 75000 | $0.00 | 75,000.0000 | 0 | 9999.99% | 0.00% |
| Nov. 27, 2024 | Luu Brendan | Chief Business Officer | A | Stock Option (right to buy) | 75000 | $0.00 | 75,000.0000 | 0 | 9999.99% | 0.00% |
| Nov. 27, 2024 | Kieffer Tara Lynn | Chief Product Strategy Officer | A | Stock Option (right to buy) | 81000 | $0.00 | 81,000.0000 | 0 | 9999.99% | 0.00% |
| Nov. 27, 2024 | Rottinghaus Scott T. | Chief Medical Officer | A | Stock Option (right to buy) | 87000 | $0.00 | 87,000.0000 | 0 | 9999.99% | 0.00% |
| Nov. 27, 2024 | Or Yat Sun | Chief Scientific Officer | A | Stock Option (right to buy) | 87000 | $0.00 | 87,000.0000 | 0 | 9999.99% | 0.00% |
| Nov. 27, 2024 | Luly Jay R. | President and CEO | A | Stock Option (right to buy) | 250000 | $0.00 | 250,000.0000 | 0 | 9999.99% | 0.00% |
| Aug. 8, 2023 | Rottinghaus Scott T. | Chief Medical Officer | F | Common Stock | 1467 | $17.23 | 25,533.0000 | 0 | 5.43% | 0.00% |
| Aug. 8, 2024 | Rottinghaus Scott T. | Chief Medical Officer | F | Common Stock | 1466 | $12.73 | 18,784.0000 | 0 | 7.24% | 0.00% |
| July 15, 2024 | Rottinghaus Scott T. | Chief Medical Officer | S | Common Stock | 5375 | $17.08 | 21,717.0000 | 0 | 19.84% | 0.00% |
| July 15, 2024 | Rottinghaus Scott T. | Chief Medical Officer | M | Stock Option (Right to Buy) | 5375 | $0.00 | 80,625.0000 | 0 | 6.25% | 0.00% |
| July 15, 2024 | Rottinghaus Scott T. | Chief Medical Officer | M | Common Stock | 5375 | $8.99 | 27,092.0000 | 0 | 24.75% | 0.00% |
| July 12, 2024 | Rottinghaus Scott T. | Chief Medical Officer | S | Common Stock | 2271 | $15.04 | 21,717.0000 | 0 | 9.47% | 0.00% |
| July 11, 2024 | Rottinghaus Scott T. | Chief Medical Officer | S | Common Stock | 4299 | $15.07 | 23,988.0000 | 0 | 15.20% | 0.00% |
| June 17, 2024 | Kieffer Tara Lynn | Chief Product Strategy Officer | S | Common Stock | 7266 | $12.33 | 32,341.0000 | 0 | 18.35% | 0.00% |
| April 29, 2024 | Kowalsky Matthew Paul | Chief Legal Officer | A | Stock Option (right to buy) | 150000 | $0.00 | 150,000.0000 | 0 | 9999.99% | 0.00% |
| March 6, 2024 | CARTER BRUCE L A | Director | A | Stock Option (right to buy) | 15700 | $0.00 | 15,700.0000 | 0 | 9999.99% | 0.00% |
| March 6, 2024 | Vance Terry | Director | A | Stock Option (right to buy) | 15700 | $0.00 | 15,700.0000 | 0 | 9999.99% | 0.00% |
| March 6, 2024 | Peterson Kristine | Director | A | Stock Option (right to buy) | 15700 | $0.00 | 15,700.0000 | 0 | 9999.99% | 0.00% |
| March 6, 2024 | FOLETTA MARK G | Director | A | Stock Option (right to buy) | 15700 | $0.00 | 15,700.0000 | 0 | 9999.99% | 0.00% |
| March 6, 2024 | Russell Lesley | Director | A | Stock Option (right to buy) | 15700 | $0.00 | 15,700.0000 | 0 | 9999.99% | 0.00% |
| March 6, 2024 | Hata Yujiro S | Director | A | Stock Option (right to buy) | 15700 | $0.00 | 15,700.0000 | 0 | 9999.99% | 0.00% |
| Feb. 26, 2024 | Gardiner Nathaniel S. | Chief Legal Officer | M | Stock Option (Right to Buy) | 5187 | $0.00 | 77,813.0000 | 0 | 6.25% | 0.00% |
| Feb. 26, 2024 | Gardiner Nathaniel S. | Chief Legal Officer | M | Common Stock | 5187 | $8.99 | 111,614.0000 | 0 | 4.87% | 0.00% |
| Feb. 12, 2024 | Rottinghaus Scott T. | Chief Medical Officer | F | Common Stock | 755 | $12.41 | 28,287.0000 | 0 | 2.60% | 0.00% |
| Feb. 12, 2024 | Or Yat Sun | Chief Scientific Officer | A | Common Stock | 3680 | $0.00 | 374,375.0000 | 0 | 0.99% | 0.00% |
| Feb. 12, 2024 | Or Yat Sun | Chief Scientific Officer | F | Common Stock | 1080 | $12.41 | 373,295.0000 | 0 | 0.29% | 0.00% |
| Feb. 12, 2024 | MELLETT PAUL J | Chief Fin. & Admin Officer | A | Common Stock | 3320 | $0.00 | 96,869.0000 | 0 | 3.55% | 0.00% |
| Feb. 12, 2024 | Luly Jay R. | President and CEO | F | Common Stock | 1584 | $12.41 | 810,609.0000 | 0 | 0.20% | 0.00% |
| Feb. 12, 2024 | MELLETT PAUL J | Chief Fin. & Admin Officer | F | Common Stock | 973 | $12.41 | 95,896.0000 | 0 | 1.00% | 0.00% |
| Feb. 12, 2024 | Luly Jay R. | President and CEO | A | Common Stock | 5400 | $0.00 | 812,193.0000 | 0 | 0.67% | 0.00% |
| Feb. 12, 2024 | Luu Brendan | Chief Business Officer | A | Common Stock | 3320 | $0.00 | 40,056.0000 | 0 | 9.04% | 0.00% |
| Feb. 12, 2024 | Luu Brendan | Chief Business Officer | F | Common Stock | 973 | $12.41 | 39,083.0000 | 0 | 2.43% | 0.00% |
| Feb. 12, 2024 | Kieffer Tara Lynn | Chief Product Strategy Officer | A | Common Stock | 3320 | $0.00 | 40,580.0000 | 0 | 8.91% | 0.00% |
| Feb. 12, 2024 | Kieffer Tara Lynn | Chief Product Strategy Officer | F | Common Stock | 973 | $12.41 | 39,607.0000 | 0 | 2.40% | 0.00% |
| Feb. 12, 2024 | Gardiner Nathaniel S. | Chief Legal Officer | A | Common Stock | 3320 | $0.00 | 107,400.0000 | 0 | 3.19% | 0.00% |
| Feb. 12, 2024 | Gardiner Nathaniel S. | Chief Legal Officer | F | Common Stock | 973 | $12.41 | 106,427.0000 | 0 | 0.91% | 0.00% |
| Feb. 12, 2024 | Rottinghaus Scott T. | Chief Medical Officer | A | Common Stock | 2576 | $0.00 | 29,042.0000 | 0 | 9.73% | 0.00% |